← Galderma Group AG/ADR (GDERF) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Galderma Group AG/ADR (GDERF)
Biotechnology · market cap $48.6B · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-15 (est.)
Phase 2
Pipeline
10
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Galderma Group AG (GDERF) is a dermatology-focused company with a market cap of approximately $48.7B, operating across aesthetics, dermatological therapeutics, and dermocosmetics. Its pipeline spans multiple Phase 2 and Phase 3 programs including botulinum toxin neuromodulators, nemolizumab for atopic dermatitis, and CD07805/47 gel for rosacea, positioning it as a broad-spectrum dermatology platform rather than a single-asset bet.
The catalyst path
- 2026-12-15 (est.)Phase 2 · Nemolizumabimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| botulinum toxin | Phase 3 | Lateral Canthal Lines |
| Nemolizumab | Phase 3 | Moderate-to-Severe Atopic Dermatitis |
| Botulinum Toxin Type A | Phase 2 | Glabellar Frown Lines |
| Metvix® cream | Phase 3 | Basal Cell Carcinoma |
| Adapalene | Phase 2 | Acne Scars |
| CD 2027 | Phase 2 | Plaque-type Psoriasis |
| botulinum toxin neuromodulator | Phase 3 | Glabellar Frown Lines (GL) |
| CD07805/47 gel | Phase 3 | Rosacea |
| QM1114-DP | Phase 3 | Glabellar Frown Lines |
| clobetasol propionate shampoo (2/week) | Phase 3 | Scalp Seborrheic Dermatitis |
Price & technical context
3-month
-11.5%
6-month
-2.9%
12-month
+13.4%
52-wk range
$167.00–$245.97
vs 50-day MA
-8.8%
vs 200-day MA
-7.3%
Realized vol
69.7%
Max drawdown
-25.2%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for GDERF (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 10 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.